[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"moderate-dementia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:moderate-dementia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100608946","share-adaptation-intervention-for-african-american-families-100608946",false,"NCT07208162","SHARE Adaptation Intervention for African-American Families","Adapting the SHARE for Dementia Early-Stage Dyadic Intervention: A Stage I Pilot Study With African-American Families","SHARE","Inclusion Criteria:\n\n* African American dyads (both the caregivers and the care-recipient, an individual with an early-stage memory impairing condition (e.g., Alzheimer's disease, vascular dementia, cognitive impairment, etc.)\n* Care-recipient lives at home.\n* The caregiver (CG) and\u002For the person with dementia (PWD), or symptoms of memory loss must identify as African American.\n* PWD must be at least 50 years old and CGs 18 or older,\n* Ability to speak and read English,\n* Experiencing signs and symptoms of mild to moderate dementia through family caregiver report on the Dementia Severity Rating Scale and meeting the National Institute on Aging and the Alzheimer's Association clinical criteria for probable AD.\n\nExclusion Criteria:\n\n* A mental health condition (e.g., schizophrenia, bipolar disorder, major depression)\n* A traumatic brain injury\n* Intellectual or developmental disability\n* Individuals experiencing extreme difficulty adjusting and coping to the diagnosis • Individuals living in an institutional setting","ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","This project aims to culturally adapt the SHARE program for African-Americans in early-moderate stage dementia and their care partner. Upon completion of the adaptation, a pilot randomized-control trial wil be confucted to compare the adaptaed SHARE program versus usual care.",[27,28],"Mild Dementia","Moderate Dementia","RECRUITING","2025-09-28",{"date":32,"type":33},"2025-10-06","ACTUAL",{"date":35,"type":33},"2025-08-19",{"date":37,"type":21},"2026-07",{"name":39,"class":40},"Benjamin Rose Institute on Aging","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100400946","phase-1-repurposing-nucleoside-reverse-transcriptase-inhibitors-for-treatment-of-ad-100400946","NCT04500847","Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD","LINE-AD","Inclusion Criteria:\n\n* Male or female, ages 50-85 years inclusive\n* Intellectually, visually and auditory capable, fluent in, and able to read, the language in which study assessments are administered (e.g. completion of at least six years of regular schooling or sustained employment or equivalent local level of knowledge).\n* Must meet NIA-AA research criteria for MCI and mild dementia due to AD\n* Mini Mental State Exam (MMSE) 15-30 inclusive\n* Clinical Dementia Rating (CDR) 0.5 - 2\n* Must meet a cerebrospinal fluid (CSF) pTau\u002FAβ42 ratio of \\> 0.024\n* Participants must have an appropriate study partner who agrees to participate in the study and who is intellectually, visually, and auditory capable, and fluent in, and able to read, the language in which study assessments are administered. Additionally, the study partner must be capable of and willing to: Accompany the participant to visits that requires the input of the study partner\n* Concurrent treatment with cholinesterase inhibitors and memantine are permitted on a stable dose for at least 60 days prior to baseline.\n\nExclusion Criteria:\n\n* Current medical or neurological condition that might impact cognition or performance on cognitive assessments, e.g., Huntington's disease, Parkinson's disease, syphilis, schizophrenia, bipolar disorder, active major depression, attention deficit\u002F hyperactivity disorder (ADD\u002FADHD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), active seizure disorder, current alcohol\u002Fdrug abuse or dependence, or dependence within the last two years, or history of traumatic brain injury associated with loss of consciousness and ongoing residual transient or permanent neurological signs\u002Fsymptoms including cognitive deficits, and\u002For associated with skull fracture\n* Brain MRI results showing findings unrelated to AD that, in the opinion of the investigator might be a leading cause of future cognitive decline, might pose a risk to the participant, or might confound MRI assessment for safety monitoring\n* Score \"yes\" on item four or item five of the Suicidal Ideation section of the Columbia Suicide Severity Rating Scale (eC-SSRS patient-reported outcome), if this ideation occurred in the past six months, or \"yes\" on any item of the Suicidal Behavior section, except for the \"Non-Suicidal Self-Injurious Behavior\" (item is included in the Suicidal Behavior section), if this behavior occurred in the past 2 years prior to screening\n* Use of other investigational drugs prior to screening until:\n\n  * Small molecules: after five half-lives, or within 30 days until the expected pharmacodynamic effect has returned to baseline, whichever is longer\n  * Biologicals: blood concentration has returned to baseline (or below serological responder threshold) for antibodies induced by active immunotherapy; or five half- lives for monoclonal antibodies or other biologicals\n* Approximately four weeks prior to randomization, the use of any drug or treatment known for the potential to cause major organ system toxicity, i.e. drugs that may require periodic safety monitoring of a specific organ or body fluid. Examples include, but are not limited to clozapine, cancer medical treatment like tamoxifen, systemic immunosuppressive drugs like methotrexate or interferon, or other immunosuppressive biological medicines for rheumatic diseases or multiple sclerosis\n* A positive drug screen, if, in the investigator's opinion, this is due to drug abuse or dependence.\n* Significant ECG findings that are assessed as clinically significant by the investigator (e.g. sustained ventricular tachycardia, significant second or third degree atrioventricular block without a pacemaker, long QT syndrome or clinically meaningful prolonged QT interval).\n* Contraindication to lumbar puncture including use of anti-coagulants, low platelet count, history of back surgery (with the exception of microdiscectomy or laminectomy over one level), signs or symptoms of intracranial pressure, spinal deformities or other spinal conditions that in the judgment of the investigator would preclude a lumbar puncture\n* History of or active hepatitis or HIV infection (based on a positive lab result for HBV and\u002For HIV, to be performed during screening\n* Severe renal impairment\n* Severe hepatic impairment\n* Significant cardiac disease including recent (within six months) myocardial infarction, congestive heart failure or unstable angina\n* Female subjects who are pregnant or currently breastfeeding.","50 Years","85 Years",{"count":52,"type":21},35,[54],"PHASE1","This is a randomized, double-blind clinical trial of a daily oral dose of 200 mg emtricitabine vs. placebo in 35 participants with biomarker-confirmed MCI or mild to moderate dementia due to Alzheimer's disease. Study duration for each subject participating in the placebo-controlled research study will be approximately 12 months (up to a 3 months Screening Period, Baseline visit (1 month), 6 months of placebo or emtricitabine dosing, and 1 month follow-up). Participants will have up to 2 months to complete all procedures for the month 6 study visit.",[57,58,28],"Alzheimer Disease, Early Onset","Mild Cognitive Impairment","2025-05-01",{"date":61,"type":33},"2025-05-04",{"date":63,"type":33},"2021-12-17",{"date":65,"type":21},"2026-03-31",{"name":67,"class":40},"Butler Hospital",2,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":75,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":41},"100564691","phase-1-clinical-utility-and-safety-of-human-umbilical-cord-mesenchymal-stem-cell-secretome-in-moderate-neurocognitive-impairment-dementia-100564691","NCT06632470","Clinical Utility and Safety of Human Umbilical Cord Mesenchymal Stem Cell Secretome in Moderate Neurocognitive Impairment (Dementia)","Inclusion Criteria:\n\n1. Age \\> 60 years old\n2. Patient diagnosed with dementia confirmed by psychiatrist or neurologist based on DSM-4 or ICD 10\n3. Patient with Mini-Mental State Examination (MMSE) between 10 to 20 indicating moderate cognitive impairment\n4. Patient is in stable condition without life threatening disease or uncontrolled medical condition\n5. Patient undergoing stable dose treatment for other medical condition at least 4 months before the trial\n6. Patient with care giver or supporting family who can assist patient with research protocol\n\nExclusion Criteria:\n\n1. Patient has dementia due to other medical condition such as severe head trauma, brain infection or history of drug abuse\n2. Patient with uncontrolled medical condition such as severe cardiovascular disease, chronic lung disease, cancer, or systemic infection\n3. Patient with severe psychiatry disorder such as schizophrenia and bipolar disorder\n4. Patient is receiving experimental drugs or participates in experimental studies for the last 30 days before the trial\n5. Patient who has allergy or hypersensitivity reaction towards secretome\n6. Patient with medical complications or surgery complications that require immediate interventions or other life threatening complications\n7. Patient is unable to provide written informed consent and not capable to understand and comply to research protocol\n8. Patient is unwilling and not capable to follow research protocol including follow up evaluations and blood sampling according to schedule","60 Years",{"count":77,"type":21},54,[54],"The goal of this clinical trial if to learn if Human Umbilical Cord Mesenchymal Stem Cell (HUCMSC) derived secretome injection is safe and effective in patient with moderate dementia. The main questions it aims to answer are:\n\n1. Is HUCMSC derived secretome safe to be use as a therapy in patients with moderate dementia?\n2. How does HUCMSC derived secretome affect pro inflammatory and anti inflammatory cytokine (IL-6 and TNF alfa) in patient with moderate dementia?\n3. What is the relationship between HUCMSC derived secretome therapy with mini mental state examination? Researchers will compare the intervention group (patients who are injected with HUCMSC derived secretome) and control group (patients who are only monitored)\n\nParticipants will\n\n* Be injected with HUCMSC derived secretome or Vitamin B12 every two weeks for 4 months\n* Follow up visit to review treatment progress on 3rd months (2 weeks post treatment), 7th months (3 months post treatment) and participants will do several blood test and mental examination",[81,28],"Dementia",[83,84,85,86,87,88],"dementia","moderate dementia","neurocognitive impairment","secretome","HUCSMC","stem cells","NOT_YET_RECRUITING","2024-10-07",{"date":92,"type":33},"2024-10-09",{"date":94,"type":21},"2024-10-15",{"date":96,"type":21},"2025-10-01",{"name":98,"class":40},"Baermed"]